Discover more from FarmaKology’s Substack
FarmaKology-Omicron InfectionsWithout Vaccinations Provide Little Immunity
Hikma help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture of progress and belonging, being one Hikma, supporting each other, driving onwards, growing Hikma and living by our three values of innovate, care and collaborate. Delivering on our strategic goals of delivering more from our foundation, building a portfolio that anticipates future health needs and inspiring and enabling our people. And acting responsibly, driving positive impact. We advance health and wellbeing, we empower our people, we protect the environment, and we build trust through quality in everything we do. We are a trusted, reliable partner and dependable source of over 670 high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 32 manufacturing facilities, 7 R&D centres and 8,700+ employees worldwide.
Evotec SE and Almirall S.A., a global biopharmaceutical company focused on skin health, announced today a multi-target alliance in Medical Dermatology. The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma.
Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer
Mersana Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to XMT-2056, the company’s lead Immunosynthen STING-agonist ADC, for the treatment of gastric cancer.
BioMoti Ltd today announces an agreement with a global pharmaceutical company to collaborate on the development of its lead ovarian cancer candidate, BMT101, to clinical phase 2a proof-of-concept. The collaboration agreement provides access to the partner company’s expertise including its proprietary commercial manufacturing technology and an option for the global pharmaceutical company to license BMT101 in specific territories.
Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System
Myeloid Therapeutics, Inc. , a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it has entered into an agreement with Acuitas Therapeutics ("Acuitas"), a global leader in developing LNP delivery systems that enable mRNA-based therapeutics.
Research & Study
Cancer death rates among Black people declined over time, but remain higher than other racial and ethnic groups
Biotechs have seen their valuations take a plunge, triggering layoffs and pipeline cuts, but Big Pharma is not yet tempted to go on an M&A spree. CEOs of many of the world’s biggest pharma companies point out that biotech prices still have a way to drop before they become truly attractive buys. Also under discussion is Fierce's annual report on the highest paid biopharma R&D executives. This year, the list doesn’t look anything like it has in the past except for the fact that it continues to be comprised of white men. And the quarterly earnings calls are the buzz around the newsroom this week—but not in the way you might think.